# Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

> **NCT03811457** · NA · COMPLETED · sponsor: **UWELL Biopharma** · enrollment: 9 (actual)

## Conditions studied

- Lymphoma Leukemia

## Interventions

- **GENETIC:** Welgenaleucel

## Key facts

- **NCT ID:** NCT03811457
- **Lead sponsor:** UWELL Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811457, "Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03811457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*